Sharon Abrahams
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sharon Abrahams has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Caroline McHutchison
School of Psychology, Faculty of Natural Sciences, University of Stirling, Stirling, UK
2 shared publications - Joke De Vocht
Department of Neurosciences, Experimental Neurology, Leuven Brain Institute, KU Leuven , Leuven 3000
2 shared publications - Philip Van Damme
Laboratory of Neurobiology, Department of Neuroscience, KU Leuven, Leuven, Belgium
2 shared publications - Alberto Benussi
Neurology Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy
1 shared publication - Bradley F. Boeve
Mayo Clinic Rochester
1 shared publication - Chiadi Onyike
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, MD
1 shared publication
Latest Publications
- Open Access
- 10 September 2026
- Published by Oxford University Press (OUP) in Brain
Conceptualizing cognition and behaviour across amyotrophic lateral sclerosis and frontotemporal dementia
Cognitive and behavioural dysfunction in frontotemporal dementia (FTD) evolves along a clinical continuum from a clinically silent stage of disease, through a prodromal period, often referred to as mild cognitive impairment (MCI) and/or mild behavioural impairment (MBI), and into a clinically manifest stage recognized by the syndromes of behavioural variant FTD and primary progressive aphasia (PPA). Similar cognitive and behavioural manifestations of varying severity are also encountered in individuals with amyotrophic lateral sclerosis (ALS). Notwithstanding this phenotypic overlap as well as a degree of shared genetic risk and underlying pathology, the approach to phenotypic characterization and description meaningfully differs between the ALS and FTD communities. The problem is particularly evident within the ALS community when describing impairment in the prodromal versus clinically manifest disease stages. Pertinent considerations include the nature of cognitive and behavioural assessments, the nosology used to describe symptoms identified, including those encompassed by the terms ‘behavioural’ and ‘neuropsychiatric’, the operationalized criteria that define prodromal syndromes and clinically manifest disease, and the extent to which these criteria rely on longitudinal (versus cross-sectional) data. A multi-stakeholder workshop, held in London, Ontario (12–14 May 2025), brought together neurologists, psychiatrists, neuropsychologists, neuropathologists, neuroscientists and neurogeneticists studying ALS and FTD, to promote interdisciplinary dialogue and to define a research agenda that might be jointly tackled to address these critical issues. A new nosology for classifying frontotemporal-related behavioural and neuropsychiatric dysfunction, which could be used to support empirical evidence collection, is proposed alongside a list of cognitive, language, behavioural and neuropsychiatric symptoms to be considered in the evaluation of individuals with ALS. Research priorities for each of the ALS and FTD communities, as well as initiatives that should be undertaken jointly, are highlighted. The long-term goal is to harmonize approaches to phenotypic characterization, the nosology used to describe symptoms and the criteria used to define landmark stages along the clinical continua of the motor neuron and frontotemporal axes, irrespective of clinical stage.
- 10 September 2026
- Published by Oxford University Press (OUP) in Brain
Open AccessConceptualizing cognition and behaviour across amyotrophic lateral sclerosis and frontotemporal dementia
Cognitive and behavioural dysfunction in frontotemporal dementia (FTD) evolves along a clinical continuum from a clinically silent stage of disease, through a prodromal period, often referred to as mild cognitive impairment (MCI) and/or mild behavioural impairment (MBI), and into a clinically manifest stage recognized by the syndromes of behavioural variant FTD and primary progressive aphasia (PPA). Similar cognitive and behavioural manifestations of varying severity are also encountered in individuals with amyotrophic lateral sclerosis (ALS). Notwithstanding this phenotypic overlap as well as a degree of shared genetic risk and underlying pathology, the approach to phenotypic characterization and description meaningfully differs between the ALS and FTD communities. The problem is particularly evident within the ALS community when describing impairment in the prodromal versus clinically manifest disease stages. Pertinent considerations include the nature of cognitive and behavioural assessments, the nosology used to describe symptoms identified, including those encompassed by the terms ‘behavioural’ and ‘neuropsychiatric’, the operationalized criteria that define prodromal syndromes and clinically manifest disease, and the extent to which these criteria rely on longitudinal (versus cross-sectional) data. A multi-stakeholder workshop, held in London, Ontario (12–14 May 2025), brought together neurologists, psychiatrists, neuropsychologists, neuropathologists, neuroscientists and neurogeneticists studying ALS and FTD, to promote interdisciplinary dialogue and to define a research agenda that might be jointly tackled to address these critical issues. A new nosology for classifying frontotemporal-related behavioural and neuropsychiatric dysfunction, which could be used to support empirical evidence collection, is proposed alongside a list of cognitive, language, behavioural and neuropsychiatric symptoms to be considered in the evaluation of individuals with ALS. Research priorities for each of the ALS and FTD communities, as well as initiatives that should be undertaken jointly, are highlighted. The long-term goal is to harmonize approaches to phenotypic characterization, the nosology used to describe symptoms and the criteria used to define landmark stages along the clinical continua of the motor neuron and frontotemporal axes, irrespective of clinical stage.
- Open Access
- 6 January 2026
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 27 (5-6) , 1-4
Prioritizing neuropsychological research and care in Amyotrophic Lateral Sclerosis (ALS): building an international neuropsychological framework for ALS
- 6 January 2026
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 27 (5-6) , 1-4
Open AccessPrioritizing neuropsychological research and care in Amyotrophic Lateral Sclerosis (ALS): building an international neuropsychological framework for ALS